State Street’s Prelude Therapeutics PRLD Stock Holding History

State Street’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.29M	Buy	428,787 +290,556	+210%	+$1.26M	﹤0.01%	3301
2026 Q1	$473K	Buy	138,231 +10,939	+9%	+$28.7K	﹤0.01%	3670
2025 Q4	$369K	Buy	127,292 +29,700	+30%	+$50.1K	﹤0.01%	3757
2025 Q3	$141K	Hold	97,592	–	–	﹤0.01%	3987
2025 Q2	$79K	Sell	97,592 -188,454	-66%	-$163K	﹤0.01%	4017
2025 Q1	$220K	Sell	286,046 -7,350	-3%	-$6.86K	﹤0.01%	3798
2024 Q4	$374K	Buy	293,396 +7,350	+3%	+$9.75K	﹤0.01%	3698
2024 Q3	$592K	Buy	286,046 +74,300	+35%	+$344K	﹤0.01%	3566
2024 Q2	$807K	Buy	211,746 +305	+0.1%	+$1.24K	﹤0.01%	3498
2024 Q1	$1M	Sell	211,441 -793	-0.4%	-$3.08K	﹤0.01%	3473
2023 Q4	$906K	Buy	212,234 +25,025	+13%	+$76.2K	﹤0.01%	3499
2023 Q3	$578K	Buy	187,209 +3,400	+2%	+$12.8K	﹤0.01%	3635
2023 Q2	$827K	Buy	183,809 +139,920	+319%	+$836K	﹤0.01%	3611
2023 Q1	$250K	Hold	43,889	–	–	﹤0.01%	3983
2022 Q4	$265K	Hold	43,889	–	–	﹤0.01%	4004
2022 Q3	$290K	Hold	43,889	–	–	﹤0.01%	3978
2022 Q2	$229K	Sell	43,889 -165,972	-79%	-$845K	﹤0.01%	4134
2022 Q1	$1.45M	Buy	209,861 +1,455	+0.7%	+$13.3K	﹤0.01%	3680
2021 Q4	$2.6M	Sell	208,406 -642,077	-75%	-$10.4M	﹤0.01%	3559
2021 Q3	$26.6M	Sell	850,483 -201,733	-19%	-$6.53M	﹤0.01%	2273
2021 Q2	$30.1M	Buy	1,052,216 +178,840	+20%	+$6.37M	﹤0.01%	2223
2021 Q1	$37.8M	Buy	873,376 +731,043	+514%	+$48.5M	﹤0.01%	1949
2020 Q4	$10.2M	Buy	+142,333	New	+$7.08M	﹤0.01%	2621

Other funds holding PRLD

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

State Street's PRLD Position: Q2 2026 in Review

State Street increased its Prelude Therapeutics (PRLD) stake by 210% in Q2 2026, buying an estimated $1.26M and bringing the position to 428,787 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3301.

State Street first reported a position in PRLD in Q4 2020 and has held it in 23 quarters since. The position peaked at $37.8M in Q1 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

State Street held 428,787 shares of Prelude Therapeutics worth $2.29M as of Q2 2026.
State Street bought 290,556 Prelude Therapeutics shares in Q2 2026, an estimated $1.26M.
Prelude Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3301 holding.
State Street first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 23 quarters since.
State Street's Prelude Therapeutics position peaked at $37.8M in Q1 2021.
75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.